Man

Christian Lorenzo Caglevic Medina

Director Científico

Fundación Arturo Lopez Perez

Santiago, Chile

Líneas de Investigación


Participación en clinical trials desde 2008 en cáncer

Educación

  •  Oncology, UNIVERSIDAD DE SANTIAGO DE CHILE. Chile, 2008

Experiencia Académica

  •   Director Cientifico Departamento de Investigacion del cancer Full Time

    Santiago, Chile

    2020 - A la fecha

Experiencia Profesional

  •   Academic Part Time

    Universidad de Chile

    Santiago, Chile

    2002 - 2009

  •   Medical Oncologist Part Time

    Hospital Barros Luco Trudeau

    Santiago, Chile

    2004 - 2012

  •   Medical Oncologist Part Time

    Hospital Clínico Universidad de Chile

    Santiago, Chile

    2007 - 2009

  •   Medical Oncologist Part Time

    Fundación Arturo Lopez Perez de Santiago (2009-2018)

    Santiago, Chile

    2009 - 2018

  •   Medical Oncologist Full Time

    Clinica Alemana Santiago

    Santiago, Chile

    2018 - 2020

  •   Head of lnvestigational Cancer Drugs Unit (UIDO- FALP) Part Time

    Fundación Arturo Lopez Perez

    Santiago, Chile

    2016 - 2018

  •   Head of Cancer Research Department Full Time

    Fundación Arturo Lopez Perez

    Santiago, Chile

    2020 - A la fecha

Formación de Capital Humano


Experiencia en Investigación clínica, Director Científico de Departamento de Investigación del Cáncer
A cargo de Unidad de Estudios Clínicos, Unidad de Investigación y Docencia, Unidad de Medicina Traslacional
Fundacion Arturo Lopez Perez



 

Article (39)

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
The current situation for gastric cancer in Chile
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Clinical characterization and treatment of head and neck mucosal melanoma: a Chilean experience
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
Incidence of lung cancer and air pollution in boroughs of Chile: an ecological study
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
[Cancer immunotherapy: an update]
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8 + T Cells
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group
Barriers in Latin America for the management of locally advanced breast cancer
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears
Oncogenic role of arsenic exposure in lung cancer: A forgotten risk factor
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Triple-negative breast cancer: the reality in Chile and in Latin America
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
Vaccine and immune cell therapy in non-small cell lung cancer
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology]
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
Hepatocellular carcinoma in identical twins in Chile: case report
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
Nintedanib in non-small cell lung cancer: from preclinical to approval
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer
Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer
Report from the First Latin American Urological Oncology Symposium (SLAURO) 19-21 June 2014, Viña del Mar, Chile
Latin american symposium on oncological gastroenterology
[Relapse of Hodgkin disease after 17 years of complete remission. A case report]
39
Christian Caglevic

Director Científico

Departamento de Investigación del Cáncer

Fundación Arturo Lopez Perez

Santiago, Chile